These COVID-19 clinical trials are active and approved by Health Canada. Many more are pending approval and will be added in the days and weeks ahead.
Help us complete the circle. Add your trial to our list of active COVID-19 Canadian clinical trials and gain access to a wider participant registry.
This study is for people who are hospitalized for COVID-19. All study participants will get convalescent plasma (a part of blood) to see if it prevents death and reduces intubation, and to see whether people are able to leave the intensive care unit and the hospital faster.
This study is for people with COVID-19 who are not hospitalized. The study compares hydroxychloroquine and placebo to see if people who take hydroxychloroquine are less likely to be hospitalized or die.
This study is for people who are hospitalized with COVID-19. Study participants will receive either (1) tocilizumab with standard of care, or (2) standard of care, to see if tocilizumab prevents death and improves clinical symptoms.
This study is for children hospitalized with COVID-19. Study participants will know which therapy they receive, and it will be either (1) standard of care, or (2) convalescent plasma and standard of care. The study is to see if convalescent plasma improves clinical symptoms of COVID-19 and to see if it prevents death.
This study tests whether hydroxychloroquine can (1) prevent COVID-19 after someone has been exposed to SARS-CoV-2 coronavirus, and (2) prevent hospitalizations and severe symptoms in people who have tested positive for COVID-19. People in the study with take hydroxychloroquine or a placebo.
This study is for people who are admitted in the hospital with COVID-19. The study compares 4 different treatments to prevent death and improve clinical symptoms. The study participants will know which treatment they are getting, which will be one of: (1) standard care, (2) lopinavir/ritonavir with standard care, (3) hydroxychloroquine with standard care, or (4) remdesivir with standard care.